Goldman Sachs Group Inc Forte Biosciences, Inc. Transaction History

Goldman Sachs Group Inc

$605 Billion
Q3 2024

Shares

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2024 Aug 13, 2024	BUY	$0.46 - $0.78 $0 - $1	2 Added 0.01%	20,776 $11,000
Q1 2024 May 15, 2024	BUY	$0.48 - $0.85 $16 - $28	34 Added 0.16%	20,774 $14,000
Q4 2023 Feb 13, 2024	SELL	$0.38 - $0.82 $4,946 - $10,673	-13,016 Reduced 38.56%	20,740 $17,000
Q3 2023 May 14, 2024	BUY	$0.65 - $1.04 $8,460 - $13,536	13,016 Added 62.76%	33,756 $22,000
Q3 2023 Nov 14, 2023	BUY	$0.65 - $1.04 $8,409 - $13,454	12,937 Added 62.14%	33,756 $22,000
Q2 2023 May 14, 2024	BUY	$0.98 - $1.11 $193 - $218	197 Added 0.96%	20,819 $21,000
Q2 2023 Aug 14, 2023	BUY	$0.98 - $1.11 $193 - $218	197 Added 0.96%	20,819 $21,000
Q1 2023 May 14, 2024	BUY	$0.98 - $1.06 $283 - $306	289 Added 1.42%	20,622 $20,000
Q1 2023 May 11, 2023	BUY	$0.98 - $1.06 $283 - $306	289 Added 1.42%	20,622 $20,000
Q4 2022 May 14, 2024	SELL	$0.96 - $28.0 $48 - $1,400	-50 Reduced 0.25%	20,333 $20,000
Q4 2022 Feb 13, 2023	SELL	$0.96 - $28.0 $48 - $1,400	-50 Reduced 0.25%	20,333 $20,000
Q3 2022 May 14, 2024	SELL	$1.06 - $27.75 $13,164 - $344,627	-12,419 Reduced 37.86%	20,383 $22,000
Q3 2022 Nov 10, 2022	SELL	$1.06 - $27.75 $13,164 - $344,627	-12,419 Reduced 37.86%	20,383 $0
Q2 2022 May 14, 2024	BUY	$1.07 - $1.55 $12,906 - $18,696	12,062 Added 58.16%	32,802 $43,000
Q2 2022 Aug 15, 2022	BUY	$1.07 - $1.55 $5,544 - $8,032	5,182 Added 18.76%	32,802 $43,000
Q1 2022 May 16, 2022	SELL	$1.21 - $2.24 $69,720 - $129,068	-57,620 Reduced 67.6%	27,620 $40,000
Q4 2021 Feb 14, 2022	BUY	$2.02 - $3.36 $145,856 - $242,612	72,206 Added 553.98%	85,240 $182,000
Q3 2021 Nov 10, 2021	BUY	$2.96 - $36.67 $38,580 - $477,956	13,034 New	13,034 $39,000

Others Institutions Holding FBRX

# of Institutions

1

Shares Held

175K

Call Options Held

0

Put Options Held

0

Black Rock Inc. New York, NY

175K
Shares

$977,456
0.0% of portfolio

About Forte Biosciences, Inc.

Ticker FBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,340,300
Market Cap $114M
Description
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

More about FBRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.